Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 3/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725456 | 0.75 | SIGMAR1 (0.46) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL904823 | 0.75 | SIGMAR1 (0.42) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL4725450 | 0.75 | SIGMAR1 (0.42) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL7732342 | 0.75 | SIGMAR1 (0.42) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL11347558 | 0.72 | SIGMAR1 (0.43) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL7114310 | 0.69 | SIGMAR1 (0.44) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL11479514 | 0.66 | SIGMAR1 (0.35) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL21991687 | 0.66 | PDE3B (0.36) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL11349402 | 0.66 | PDE3B (0.36) | SIGMAR1ACHEBCHEMEN1USP2 | |
| SCHEMBL11471311 | 0.65 | CYP11B2 (0.35) | SIGMAR1ACHEBCHEMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217908-A1 | Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis | SRI INTERNATIONAL (US) | 2017-08-03 | — | — | US | disclosed |
| US-9663478-B2 | Benzotriazine oxides as drugs targeting Mycobacterium tuberculosis | SRI INTERNATIONAL (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2016170163-A1 | SUBSTITUTED QUINOXALINES AND BENZOTRIAZINE P70S6 KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
| EP-2800744-A1 | BENZOTRIAZINE OXIDES AS DRUGS TARGETING MYCOBACTERIUM TUBERCULOSIS | Sri International Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| WO-2013086467-A1 | BENZOTRIAZINE OXIDES AS DRUGS TARGETING MYCOBACTERIUM TUBERCULOSIS | SRI INTERNATIONAL (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150369-A1 | Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis | SRI INTERNATIONAL (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2008059259-A2 | ANTICANCER COMPOUNDS WITH A BENZO ( 1, 2, 4 ) TRIAZIN-3YL-AMINE CORE | SENTINEL ONCOLOGY LIMITED (GB) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008015429-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
| US-4368068-A | PRE- AND POSTEMERGENCE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217908-A1 | Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis | QDPR, TBCA, TBCD | SIGMAR1 760/4885ACHE 3409/4885BCHE 2262/4885 |
| US-20130150369-A1 | Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis | QDPR, TBCA, TBCD | SIGMAR1 760/4885ACHE 3409/4885BCHE 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.